Holen Sie sich die Stockscreener-App
4.5352
0.11%
0.0052
Schlusskurs vom Vortag:
$4.53
Offen:
$4.53
24-Stunden-Volumen:
633.19K
Relative Volume:
0.07
Marktkapitalisierung:
$353.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-1.4352
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-3.10%
1M Leistung:
-20.86%
6M Leistung:
-38.30%
1J Leistung:
-60.50%
1-Tages-Spanne:
$4.435
$4.56
1-Wochen-Bereich:
$4.435
$4.95
52-Wochen-Spanne:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
4.535 | 353.59M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.85 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Why Replimune Group Inc. is moving todayMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
How Replimune Group Inc. stock compares to growth peers2025 Investor Takeaways & Real-Time Sentiment Analysis - newser.com
How to build a custom watchlist for Replimune Group Inc.2025 Biggest Moves & Step-by-Step Swing Trade Plans - newser.com
Real time social sentiment graph for Replimune Group Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
Forecasting Replimune Group Inc. price range with options data2025 Technical Patterns & Risk Managed Investment Signals - newser.com
How to use a screener to detect Replimune Group Inc. breakoutsInsider Selling & Technical Entry and Exit Tips - newser.com
Will Replimune Group Inc. stock go up soon2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Tools to assess Replimune Group Inc.’s risk profileMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Will a bounce in Replimune Group Inc. offer an exit2025 Pullback Review & Capital Efficient Trade Techniques - newser.com
Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Published on: 2025-10-05 07:01:13 - newser.com
What does recent volatility data suggest for Replimune Group Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Why retail investors pile into Replimune Group Inc. stock2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com
Published on: 2025-10-03 06:54:08 - newser.com
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Strategies to average down on Replimune Group Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Will Replimune Group Inc. stock sustain high P E ratios2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - WV News
Replimune Group's (REPL) "Underweight" Rating Reiterated at JPMorgan Chase & Co. - MarketBeat
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Investigation announced for Long-Term Investors in shares - openPR.com
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism By Investing.com - Investing.com South Africa
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pend - GuruFocus
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News
2025-09-22 | Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky | NDAQ:REPL | Press Release - Stockhouse
Replimune Group, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsREPL - MarketScreener
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Se - GuruFocus
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):